SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 230,977.40 |
| Enterprise Value ($M) | 238,697.40 |
| Book Value ($M) | 40,028.00 |
| Book Value / Share | 23.08 |
| Price / Book | 5.77 |
| NCAV ($M) | -10,526.00 |
| NCAV / Share | -6.07 |
| Price / NCAV | -21.94 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.24 |
| Return on Assets (ROA) | 0.18 |
| Return on Equity (ROE) | 0.36 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.14 |
| Current Ratio | 1.60 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 23,802.00 |
| Assets | 74,356.00 |
| Liabilities | 34,328.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 41,950.00 |
| Operating Income | 7,054.00 |
| Net Income | 13,402.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.01 | 0.62 | |
| 13G/A | BlackRock, Inc. | 7.70 | -3.92 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,244,572 | 4,897,031 | 25.41 | |
| 834,228 | 3,555,470 | 23.46 | |
| 754,044 | 2,987,687 | 25.24 | |
| 1,026,159 | 3,848,767 | 26.66 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ABBV – AbbVie Inc. | ADCT – ADC Therapeutics SA |
| ANRO – Alto Neuroscience, Inc. |